Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Good post—you covered a lot of ground. We’re on the same wavelength about Hepsera: Viread will make it obsolete.

If Ns+Nt combination therapy works, Viread will have the Nt side locked up; the contest will be between Tyzeka, Baraclude, and perhaps Clevudine on the Ns side.

I’ve yet to see anything to convince me that Tyzeka won’t eventually garner a 33% molecule share of the overall HBV market. If it can do that, IDIX’s 50% stake in the U.S. and western Europe and royalties in the rest of the world will generate some serious cash flow.